Biomet lands itself a diamond deal
This article was originally published in Clinica
Executive Summary
Biomet has gained semi-exclusive, worldwide rights to develop and distribute products for total hip arthroplasty based on Diamicron's polycrystalline diamond composite (PDC) technology. The agreement also provides Warsaw, Indiana-based Biomet with option rights to use the PDC technology to develop and market other extremity joint replacement products, including knee replacements.